200 related articles for article (PubMed ID: 37815625)
1. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
Flouri I; Goutakoli P; Repa A; Bertsias A; Avgoustidis N; Eskitzis A; Pitsigavdaki S; Kalogiannaki E; Terizaki M; Bertsias G; Sidiropoulos P
Rheumatol Int; 2024 Feb; 44(2):249-261. PubMed ID: 37815625
[TBL] [Abstract][Full Text] [Related]
2. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
[TBL] [Abstract][Full Text] [Related]
3. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.
Favalli EG; Becciolini A; Carletto A; Conti F; Amato G; Fusaro E; Quartuccio L; Egan CG; Lo Monaco A; Benucci M; Salaffi F; Semeraro A; Parisi S; Ceccarelli F; Piazza I; Foti R
Rheumatol Int; 2020 Feb; 40(2):263-272. PubMed ID: 31435754
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis.
Bekele DI; Cheng E; Reimold A; Geier C; Ganuthula K; Walsh JA; Clegg DO; Dubreuil M; Kaushik P; Ng B; Chang E; Duong R; Park J; Kerr GS
Rheumatol Int; 2022 Nov; 42(11):1925-1937. PubMed ID: 34724089
[TBL] [Abstract][Full Text] [Related]
7. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
8. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
[TBL] [Abstract][Full Text] [Related]
10. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
[TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
12. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
[TBL] [Abstract][Full Text] [Related]
14. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients.
van den Brandt S; Zbinden A; Baeten D; Villiger PM; Østensen M; Förger F
Arthritis Res Ther; 2017 Mar; 19(1):64. PubMed ID: 28320445
[TBL] [Abstract][Full Text] [Related]
16. Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study.
Michelsen B; Sexton J; Wierød A; Bakland G; Rødevand E; Krøll F; Kvien TK
Semin Arthritis Rheum; 2020 Feb; 50(1):12-16. PubMed ID: 31358361
[TBL] [Abstract][Full Text] [Related]
17. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.
Favalli EG; Selmi C; Becciolini A; Biggioggero M; Ariani A; Santilli D; Fusaro E; Parisi S; Massarotti M; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2017 Jun; 69(6):867-874. PubMed ID: 27696735
[TBL] [Abstract][Full Text] [Related]
18. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries.
Egeberg A; Rosenø NAL; Aagaard D; Lørup EH; Nielsen ML; Nymand L; Kristensen LE; Thyssen JP; Thomsen SF; Cordtz RL; Loft N; Skov L; Bryld LE; Rasmussen MK; Højgaard P; Kristensen S; Dreyer L
Semin Arthritis Rheum; 2022 Apr; 53():151979. PubMed ID: 35183936
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
20. BENEFIT: real-world effectiveness of SB4 after transition from reference etanercept in rheumatoid arthritis and axial spondyloarthritis.
Selmi C; Krüger K; Cantagrel A; Abad Hernández MA; Freudensprung U; Farouk Rezk M; Addison J
Clin Exp Rheumatol; 2021; 39(2):365-371. PubMed ID: 32662409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
